A novel glycogen synthase kinase-3 inhibitor optimized for acute myeloid leukemia differentiation activity

Standard therapies used for the treatment of Acute Myeloid Leukemia (AML) are cytotoxic agents that target rapidly proliferating cells. Unfortunately, this therapeutic approach has limited efficacy and significant toxicity and the majority of AML patients still die of their disease. In contrast to t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Hu, Sophia, Ueda, Masumi, Stetson, Lindsay, Ignatz-Hoover, James, Moreton, Stephen, Chakrabarti, Amit, Xia, Zhiqiang, Karan, Goutam, de Lima, Marcos, Agrawal, Mukesh K, Wald, David N
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4936967/
https://ncbi.nlm.nih.gov/pubmed/27196775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0566
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados